Published 15 July 2008, doi:10.1136/bmj.a788
Cite this as: BMJ 2008;337:a788

Letters

Key opinion leaders

How it really works

The first 150 words of the full text of this article appear below.

Buckwell pleads for an idealised state of transparent relations between the industry and key opinion leaders.1 The reality is different. Here is a description from an internationally recognised clinical scientist about his experience with the industry. I respect his confidentiality and that of the corporation. My colleague’s experience is not atypical.

"When [the company] first began trumpeting the success of [their drug], I was asked to be on their speakers’ bureau. In a large audience ... I departed from the script I was given for the published data to note that the effect size ... was significantly lower than the [alternative treatments]. Since most [of the audience] had no idea what "effect size" is, I gave a brief explanation. That evening I received a phone call in my hotel room from [the company’s] director of the program. He chastised me for being off message and warned me not to make . . . [Full text of this article]

Bernard J Carroll, consultant

1 Pacific Behavioral Research Foundation, PO Box 223040, Carmel, CA 93922-3040, USA

bcarroll@redshift.com


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Should the drug industry work with key opinion leaders? Yes
Charlie Buckwell
BMJ 2008 336: 1404. [Extract] [Full Text] [PDF]




Access jobs at BMJ Careers
Whats new online at Student 

BMJ